Gilead Sciences Inc (GILD)
89.80
+1.17
(+1.32%)
USD |
NASDAQ |
Nov 21, 16:00
89.80
0.00 (0.00%)
After-Hours: 16:06
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 111.91B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 21.44% |
Valuation | |
PE Ratio | 997.78 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 3.972 |
Price to Book Value | 6.058 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.77 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 1.258 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 41.71% |
Profile
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics). |
URL | https://www.gilead.com |
Investor Relations URL | https://investors.gilead.com/ |
HQ State/Province | California |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Large Cap/Value |
Next Earnings Release | Feb. 06, 2025 (est.) |
Last Earnings Release | Nov. 06, 2024 |
Next Ex-Dividend Date | Dec. 13, 2024 |
Last Ex-Dividend Date | Sep. 13, 2024 |
Ratings
Profile
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics). |
URL | https://www.gilead.com |
Investor Relations URL | https://investors.gilead.com/ |
HQ State/Province | California |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Large Cap/Value |
Next Earnings Release | Feb. 06, 2025 (est.) |
Last Earnings Release | Nov. 06, 2024 |
Next Ex-Dividend Date | Dec. 13, 2024 |
Last Ex-Dividend Date | Sep. 13, 2024 |